Mutant paramyxovirus and method for production thereof

Details Mutant paramyxovirus and method for production thereof Mutant paramyxovirus and method for production thereof

2006-11-24

2010-12-28

Mosher, Mary E (Department: 1648)

Chemistry: molecular biology and microbiology

Virus or bacteriophage, except for viral vector or...

C435S320100, C435S325000, C435S239000, C536S023400, C536S023720, C530S350000

Reexamination Certificate

active

07858356

ABSTRACT:
The present invention provides a modified paramyxovirus containing a reduced amount of receptor-binding protein compared with the wild type; a method of preparing a modified paramyxovirus, comprising the following steps: (1) a step for introducing a nucleic acid that suppresses the expression of a receptor-binding protein of a paramyxovirus into an animal cell, (2) a step for infecting the paramyxovirus to the cell, and (3) a step for isolating paramyxovirus particles replicated in the cell; and a modified paramyxovirus prepared by the method of preparation mentioned above.The present invention also provides a chimera protein wherein a fusion protein of a virus has been joined or bound to a peptide that binds specifically to a cell surface marker; a nucleic acid that encodes the chimera protein; an animal cell capable of expressing the chimera protein on the cell surface thereof; a modified paramyxovirus expressing the chimera protein on the virus particle surface thereof; and a method of preparing a tissue targeting paramyxovirus, comprising: (1) a step for supplying a nucleic acid that encodes a chimera protein wherein a fusion protein of a virus has been joined or bound to a peptide that binds specifically to a cell surface marker of the target cells, (2) a step for introducing the nucleic acid supplied in (1) into an animal cell in an expressible state, and expressing the same, (3) a step for infecting a paramyxovirus to the cell, and (4) a step for isolating paramyxovirus particles replicated in the cell.

REFERENCES:
patent: 2003/0165477 (2003-09-01), Balloul et al.
patent: 2004/0029280 (2004-02-01), Sosnowski et al.
patent: 2006/0110361 (2006-05-01), Casimir
patent: 08-504091 (1996-05-01), None
patent: 2001-515493 (2001-09-01), None
patent: 2002-320475 (2002-11-01), None
patent: 2002-330774 (2002-11-01), None
patent: 2005-532075 (2005-10-01), None
patent: 94/06920 (1994-03-01), None
patent: 99/46278 (1999-09-01), None
patent: 03/029416 (2003-04-01), None
Techaarpornkul et al. “Functional Analysis of Recombinant Respiratory Syncytial Virus Deletion Mutants Lacking the Small Hydrophobic and/or Attachment Glycoprotein Gene.” Journal of Virology 75: 6825-6843, 2001.
Barik. “Control of nonsegmented negative-strand RNA virus replication by siRNA.” Virus Research 102:27-35, 2004.
Schroth-Diez et al (Journal of Virology 72:133-141, 1998).
Tao et al (Journal of Virology 74:6448-6458, 2000).
Zimmer et al (Journal of Virology 79:10467-10477, Aug. 2005).
Sato et al (FASEB Journal 14:2108-2118, 2000).
Saga et al., “Generation of HN-depleted HVJ virus particles by sIRNA” abstract of The 28thAnnual Meeting of the Molecular Biology Society of Japan, p. 561, 2005 (with English translation).
Kawachi et al., “Development of improved HVJ-E vector with high affinity to epidermal keratinocyte” abstract of The 28thAnnual Meeting of the Molecular Biology Society of Japan, p. 558, 2005 (with English translation).
Tomita et al., “Targeted gene therapy for rat glomerulonephritis using HVJ-immunoliposomes” The Journal of Gene Medicine, vol. 4, pp. 527-535, Apr. 30, 2002.
Hallak et al., “Targeted Measles Virus Vector Displaying Echistatin Infects Endothelial Cells via αvβ3 and Leads to Tumor Regression” Cancer Res., vol. 65(12), pp. 5292-5300, Jun. 15, 2005.
Supplementary European Search Report dated Aug. 19, 2010 in International (PCT) Application No. PCT/JP2006/324048.
Schlender, Jörg et al., “Respiratory Syncytial Virus (RSV) Fusion Protein Subunit F2, Not Attachment Protein G, Determines the Specificity of RSV Infection”, Journal Virology, vol. 77, No. 8, Apr. 2003, pp. 4609-4616, XP002593949.
Ren, Guijie et al., “Effects of Heptad Repeat Regions of F Protein on the Specific Membrane Fusion in Paramyxoviruses”, Intervirology, vol. 49, No. 5, Jul. 3, 2006, pp. 299-306, XP002593950.
Kawachi, Masako et al., “Development of Tissue-Targeting Hemagglutinating Virus of Japan Envelope Vector for Successful Delivery of Therapeutic Gene to Mouse Skin” Human Gene Therapy, vol. 18, No. 10, Oct. 2007, pp. 881-894, XP002593951.

Affiliated with

Also associated with

Rating

Mutant paramyxovirus and method for production thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mutant paramyxovirus and method for production thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutant paramyxovirus and method for production thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4221756